Effect of nigrostriatal damage induced by 6-hydroxydopamine on the expression of glial cell line-derived neurotrophic factor in the striatum of the rat

Neuroscience

Volumn 162, Issue 1, 2009, Pages 148-154

  Mertens, B ^a   Massie, A ^a   Michotte, Y ^a   Sarre, S ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

neurotrophins; Parkinson's disease; striatum; Western blotting

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MEDIAL FOREBRAIN BUNDLE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; WESTERN BLOTTING;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CORPUS STRIATUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MALE; MEDIAL FOREBRAIN BUNDLE; OXIDOPAMINE; POLYMERASE CHAIN REACTION; RANDOM ALLOCATION; RATS; RATS, WISTAR; RNA, MESSENGER; TIME FACTORS;

EID: 67349283981     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.04.036     Document Type: Article

References (52)

1. Abe K., and Hayashi T. Expression of the glial cell line-derived neurotrophic factor gene in rat brain after transient MCA occlusion. Brain Res 776 (1997) 230-234
2. Arvidsson A., Kokaia Z., Airaksinen M.S., Saarma M., and Lindvall O. Stroke induces widespread changes of gene expression for glial cell line-derived neurotrophic factor family receptors in the adult rat brain. Neuroscience 106 (2001) 27-41
3. Beal M.F. Experimental models of Parkinson's disease. Nat Rev 2 (2001) 325-334
4. Bjorklund A., Rosenblad C., Winkler C., and Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 4 (1997) 186-200
5. Carvey P.M., Ptak L.R., Nath S.T., Sierens D.K., Mufson E.J., Goetz C.G., and Klawans H.L. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol 120 (1993) 149-152
6. Collier T.J., Dung Ling Z., Carvey P.M., Fletcher-Turner A., Yurek D.M., Sladek Jr. J.R., and Kordower J.H. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced Parkinsonism. Exp Neurol 191 Suppl 1 (2005) S60-S67
7. Dirnagl U., Iadecola C., and Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22 (1999) 391-397
8. Du F., Li R., Huang Y., Li X., and Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22 (2005) 2422-2430
9. Dunnett S.B., and Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 (1999) A32-A39
10. Emborg M.E. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Methods 139 (2004) 121-143
11. Galeffi F., Bianchi L., Bolam J.P., and Della Corte L. The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur J Neurosci 18 (2003) 856-868
12. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., and Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380 (1996) 252-255
13. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 (2003) 589-595
14. Guo H., Tang Z., Yu Y., Xu L., Jin G., and Zhou J. Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures. Eur J Neurosci 16 (2002) 1861-1870
15. Herradon G., Ezquerra L., Nguyen T., Wang C., Siso A., Franklin B., Dilorenzo L., Rossenfeld J., Alguacil L.F., and Silos-Santiago I. Changes in BDNF gene expression correlate with rat strain differences in neuropathic pain. Neurosci Lett 420 (2007) 273-276
16. Hisaoka K., Nishida A., Koda T., Miyata M., Zensho H., Morinobu S., Ohta M., and Yamawaki S. Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 79 (2001) 25-34
17. Ho A., Gore A.C., Weickert C.S., and Blum M. Glutamate regulation of GDNF gene expression in the striatum and primary striatal astrocytes. Neuroreport 6 (1995) 1454-1458
18. Hou J.G., Lin L.F., and Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem 66 (1996) 74-82
19. Humpel C., Hoffer B., Stromberg I., Bektesh S., Collins F., and Olson L. Neurons of the hippocampal formation express glial cell line-derived neurotrophic factor messenger RNA in response to kainate-induced excitation. Neuroscience 59 (1994) 791-795
20. Inoue T., Tsui J., Wong N., Wong S.Y., Suzuki F., and Kwok Y.N. Expression of glial cell line-derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment. Brain Res 826 (1999) 306-308
21. Izurieta-Sanchez P., Sarre S., Ebinger G., and Michotte Y. Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats. Eur J Pharmacol 353 (1998) 33-42
22. Johnston T.H., and Brotchie J.M. Drugs in development for Parkinson's disease. Curr Opin Investig Drugs 5 (2004) 720-726
23. Johnston T.H., and Brotchie J.M. Drugs in development for Parkinson's disease: an update. Curr Opin Investig Drugs 7 (2006) 25-32
24. Jonkers N., Sarre S., Ebinger G., and Michotte Y. MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res 926 (2002) 149-155
25. Katoh-Semba R., Tsuzuki M., Miyazaki N., Yoshida A., Nakajima H., Nakagawa C., Kitajima S., and Matsuda M. Distribution and immunohistochemical localization of GDNF protein in selected neural and non-neural tissues of rats during development and changes in unilateral 6-hydroxydopamine lesions. Neurosci Res 59 (2007) 277-287
26. Kokaia Z., Airaksinen M.S., Nanobashvili A., Larsson E., Kujamaki E., Lindvall O., and Saarma M. GDNF family ligands and receptors are differentially regulated after brain insults in the rat. Eur J Neurosci 11 (1999) 1202-1216
27. König J.F.R., and Klippel R.A. The rat brain. A stereotaxic atlas (1963), Williams and Wilkins, Baltimore, MD
28. Kozlowski D.A., Miljan E.A., Bremer E.G., Harrod C.G., Gerin C., Connor B., George D., Larson B., and Bohn M.C. Quantitative analyses of GFRalpha-1 and GFRalpha-2 mRNAs and tyrosine hydroxylase protein in the nigrostriatal system reveal bilateral compensatory changes following unilateral 6-OHDA lesions in the rat. Brain Res 1016 (2004) 170-181
29. Le W.D., and Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease?. Drugs Aging 18 (2001) 389-396
30. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
31. Lin L.F., Rubin L.L., and Xu M. A non-peptidyl neurotrophic small molecule for midbrain dopaminergic neurons. J Neurochem 89 (2004) 1387-1395
32. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
33. Marco S., Saura J., Perez-Navarro E., Jose Marti M., Tolosa E., and Alberch J. Regulation of c-ret, GFRalpha1, and GFRalpha2 in the substantia nigra pars compacta in a rat model of Parkinson's disease. J Neurobiol 52 (2002) 343-351
34. Marini A.M., Jiang X., Wu X., Pan H., Guo Z., Mattson M.P., Blondeau N., Novelli A., and Lipsky R.H. Preconditioning and neurotrophins: a model for brain adaptation to seizures, ischemia and other stressful stimuli. Amino Acids 32 (2007) 299-304
35. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., and Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88 (1999) 1-16
36. Meurs A., Clinckers R., Ebinger G., Michotte Y., and Smolders I. Seizure activity and changes in hippocampal extracellular glutamate, GABA, dopamine and 5-HT. Epilepsy Res 78 (2008) 50-59
37. Nakajima K., Hida H., Shimano Y., Fujimoto I., Hashitani T., Kumazaki M., Sakurai T., and Nishino H. GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons. Brain Res 916 (2001) 76-84
38. Naveilhan P., ElShamy W.M., and Ernfors P. Differential regulation of mRNAs for GDNF and its receptors Ret and GDNFR alpha after sciatic nerve lesion in the mouse. Eur J Neurosci 9 (1997) 1450-1460
39. Nutt J.G., Carter J.H., Lea E.S., and Sexton G.J. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 51 (2002) 686-693
40. Ohta M., Mizuta I., Ohta K., Nishimura M., Mizuta E., Hayashi K., and Kuno S. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 272 (2000) 18-22
41. O'Neill M.J., Messenger M.J., Lakics V., Murray T.K., Karran E.H., Szekeres P.G., Nisenbaum E.S., and Merchant K.M. Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease. Int Rev Neurobiol 77 (2007) 179-217
42. Reeben M., Laurikainen A., Hiltunen J.O., Castren E., and Saarma M. The messenger RNAs for both glial cell line-derived neurotrophic factor receptors, c-ret and GDNFRalpha, are induced in the rat brain in response to kainate-induced excitation. Neuroscience 83 (1998) 151-159
43. Robelet S., Melon C., Guillet B., Saline P., and Kerkerian-Le Goff L. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J Neurosci 20 (2004) 1255-1266
44. Sakurai M., Hayashi T., Abe K., Yaginuma G., Meguro T., Itoyama Y., and Tabayashi K. Induction of glial cell line-derived neurotrophic factor and c-ret porto-oncogene-like immunoreactivity in rabbit spinal cord after transient ischemia. Neurosci Lett 276 (1999) 123-126
45. Schmidt-Kastner R., Tomac A., Hoffer B., Bektesh S., Rosenzweig B., and Olson L. Glial cell-line derived neurotrophic factor (GDNF) mRNA upregulation in striatum and cortical areas after pilocarpine-induced status epilepticus in rats. Brain Res 26 (1994) 325-330
46. Smith A.D., Antion M., Zigmond M.J., and Austin M.C. Effect of 6-hydroxydopamine on striatal GDNF and nigral GFRalpha1 and RET mRNAs in the adult rat. Brain Res 117 (2003) 129-138
47. Stromberg I., Bjorklund L., Johansson M., Tomac A., Collins F., Olson L., Hoffer B., and Humpel C. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol 124 (1993) 401-412
48. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., and Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 (1995) 335-339
49. Yuan H., Sarre S., Ebinger G., and Michotte Y. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease. Brain Res 1026 (2004) 95-107
50. Yuan H., Sarre S., Ebinger G., and Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 144 (2005) 35-45
51. Yurek D.M., and Fletcher-Turner A. Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion. Brain Res 891 (2001) 228-235
52. Zhou J., Yu Y., Tang Z., Shen Y., and Xu L. Differential expression of mRNAs of GDNF family in the striatum following 6-OHDA-induced lesion. Neuroreport 11 (2000) 3289-3293